Women who have a history of pregnancy loss, either miscarriage or stillbirth, may be at greater risk of postmenopausal cardiovascular disease (CVD), according to a recent study in The Annals of Family Medicine.
Women who have a history of pregnancy loss, either miscarriage or stillbirth, may be at greater risk of postmenopausal cardiovascular disease (CVD), according to a recent study in The Annals of Family Medicine.
Led by researchers at Brown University, the analysis was based on data from the Women’s Health Initiative cohort of 77,701 women who were evaluated from 1993 to 1998. Information on baseline reproductive history, sociodemographic, and CVD risk factors was collected. Multiple logistic regression was used to evaluate the association between 1 or 2 or more miscarriages and 1 or more stillbirths with occurrences of CVD.
In the study sample, 23,538 women (30.3%) reported a history of miscarriage; 1670 (2.2%) reported a stillbirth, and 1673 women reported a history of stillbirth and miscarriage. When compared with no stillbirth history, women with 1 or more stillbirths had an adjusted odds ratio (aOR) of 1.27 (95% confidence interval [CI], 1.07-1.51) for coronary heart disease (CHD). For women with a history of 1 miscarriage, the aOR was 1.19 (95% CI 1.08-1.32) for CHD; in women with 2 or more miscarriages the aOR was 1.18 (95% CI, 1.04-1.34). The multivariable odds ratio for ischemic stroke and stillbirths and miscarriages was not considered significant.
The researchers concluded that pregnancy loss was associated with CHD but not with ischemic stroke. Women with a history of pregnancy loss should be considered for close cardiovascular surveillance and potentially early invention. The researchers believe that further research is needed to understand the mechanisms behind theincreased risk of CVD associated with pregnancy loss.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Prenatal SSRI or SNRI discontinuation not linked to adverse psychiatric outcomes
October 8th 2024In a recent study, similar rates of adverse psychiatric-related outcomes were reported among patients with discontinuation of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors vs those without discontinuation.
Read More